The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventing several aspects of the prosthetic heart valve,...
Bystanders using a Philips HeartStart AED for a patient in sudden cardiac arrest.

Bystanders using a Philips HeartStart AED for a patient in sudden cardiac arrest.

News | Defibrillator Monitors | June 23, 2020
June 23, 2020 — Philips announced the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for...
Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Program status for the...
Signs for "Heroes work here" outside healthcare facilities and even the homes of clinicians have popped up across the country. This photo shows healthcare workers at the Lenox Health emergency room entrance being greeted to cheers and thanks for their essential service during the COVID-19 pandemic in New York City at a public thank you event May 21, 2020.

Signs for "Heroes work here" outside healthcare facilities and even the homes of clinicians have popped up across the country. This photo shows healthcare workers at the Lenox Health emergency room entrance being greeted to cheers and thanks for their essential service during the COVID-19 pandemic in New York City at a public thank you event May 21, 2020.

Blog | Coronavirus (COVID-19) | June 22, 2020
Prior to January 2020 when clinicians read about the history of the 1918 flu, and epidemiologists predicted we were...
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt. Ltd) said it acquired of the structural heart medical device...
iVascular Launches Essential Pro Coronary Drug-coated Balloon
News | Drug-Eluting Balloons | June 19, 2020
June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon...
MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal coronary angioplasty (PTCA) sirolimus drug-eluting balloon (DEB) for the treatment of coronary artery disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad range of balloon sizes, from 1.5 x 10 mm, up to 5 x 40 mm.
News | Drug-Eluting Balloons | June 18, 2020
June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal...
he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent...
Biotronik Launchs His-Bundle Pacing Tools
News | Pacemakers | June 16, 2020
June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His-...
Health Canada and the U.S. Food and Drug Administration (FDA) approved Thermedical’s degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter, currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
News | Ablation Systems | June 16, 2020
June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat...
The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. Getty Images 

Feature | Coronavirus (COVID-19) | June 15, 2020 | Dave Fornell, Editor
June 15, 2020 — The U.S. Food and Drug Administration (FDA) today revoked the emergency use authorization (EUA) that...
Videos | Heart Valve Technology | June 10, 2020
Jay Mohan, D.O., RPVI, interventional cardiology fellow at William Beaumont Hospital, Royal Oak, Michigan, created this...
The temporary COVID-19 hospital at the McCormick Place convention center in Chicago being toured by Illinois Gov. J.B. Pritzker April 3. The hospitals beds are set up in at least two of the expo halls, included two used the for annual RSNA radiology meeting in November each year. Photo by Susan Blair, U.S. Army Corps of Engineers, Chicago District

The temporary COVID-19 hospital at the McCormick Place convention center in Chicago being toured by Illinois Gov. J.B. Pritzker April 3. The hospitals beds are set up in at least two of the expo halls, included two used the for annual RSNA radiology meeting in November each year. Photo by Susan Blair, U.S. Army Corps of Engineers, Chicago District

Feature | Coronavirus (COVID-19) | April 28, 2020 | Dave Fornell, Editor
(UPDATED information added to this article June 10, 2020) April 28, 2020 — Medical conferences are where the latest...
 At Mayo, they have a small, tableside-mounted ultrasound console in the cath labs that is used for both radial and femoral vascular access. Table set up with the patient includes a sterile marker, a hemostat for marking the lower edge of the femoral head using fluoroscopy, a micropunture needle, and a still micropunture sheath.

At Mayo, they have a small, tableside-mounted ultrasound console in the cath labs that is used for both radial and femoral vascular access. Table set up with the patient includes a sterile marker, a hemostat for marking the lower edge of the femoral head using fluoroscopy, a micropunture needle and a still micropunture sheath. Photo and slides courtesy of Yader Sandoval, M.D.

Feature | Vascular Access | June 10, 2020 | Dave Fornell, Editor
Vascular access site bleeding is associated with higher complications and mortality rates. For decades femoral access...
Centricity Cardio Enterprise[1] is an integrated Cardiovascular PACS (CVPACS) and Information System (CVIS) that bridges the gaps between care areas and healthcare information systems. You get a single point of access for patient data, wave forms, images, analysis tools and physician reports – combined with powerful end-to-end management, analytics and workflow tools across the cardiovascular care pathway.
Webinar | Coronavirus (COVID-19) | June 10, 2020
The financial burden of COVID-19 has put tremendous pressure on health systems across the country. This webinar will...